Point72 Asia Singapore Pte. Ltd. Buys New Holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 105,105 shares of the company’s stock, valued at approximately $63,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Affinity Asset Advisors LLC acquired a new stake in Kezar Life Sciences in the 1st quarter valued at $1,588,000. Acadian Asset Management LLC boosted its stake in shares of Kezar Life Sciences by 42.5% in the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after purchasing an additional 534,203 shares in the last quarter. Acuitas Investments LLC boosted its stake in shares of Kezar Life Sciences by 42.8% in the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after purchasing an additional 295,956 shares in the last quarter. Marquette Asset Management LLC bought a new stake in shares of Kezar Life Sciences in the 1st quarter worth about $114,000. Finally, BNP Paribas Financial Markets increased its position in shares of Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after purchasing an additional 71,543 shares in the last quarter. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Price Performance

Kezar Life Sciences stock opened at $0.54 on Monday. The business’s fifty day moving average is $0.60 and its two-hundred day moving average is $0.70. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The firm has a market cap of $39.60 million, a P/E ratio of -0.39 and a beta of 0.20. Kezar Life Sciences, Inc. has a 52 week low of $0.52 and a 52 week high of $1.20.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Equities research analysts forecast that Kezar Life Sciences, Inc. will post -1.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Kezar Life Sciences in a research report on Wednesday, August 14th.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.